Summit and Evolva sign worldwide licensing agreement in infectious diseases for imino sugar compound SMT 14400

08-Jan-2009 - United Kingdom

Summit Corporation plc announced that it has entered into an exclusive worldwide licensing agreement with the Swiss company, Evolva Biotech SA. The agreement covers SMT 14400, a second-generation imino sugar, which is being developed as a potential treatment for infectious diseases associated with bio-terrorism. The licensing agreement supersedes the co-development agreement entered into by the two companies in July 2007.

Under the terms of the licence, Summit will receive an undisclosed payment from Evolva on signature. Summit will also receive payments throughout preclinical development, a milestone payment on filing of an IND (anticipated in 2010), and further development and regulatory milestone payments. Evolva will be responsible for all development costs with the initial synthesis work being contracted to Summit’s subsidiary services business, Dextra Laboratories. On successful commercialisation, Summit will receive tiered royalties, rising to a low-teen percentage, and sales-related milestone payments.

SMT 14400 originated from Summit’s proprietary collection of second-generation imino sugars that it is developing in a range of therapeutic areas. The compound is an immunomodulator that works by selectively boosting aspects of the human immune system. Evaluation of SMT 14400 by Evolva in recent in vivo preclinical studies with a selection of pathogens potentially associated with bio-terrorism has shown the compound to be active against both viral and bacterial pathogens, and to be well tolerated.

https://www.bionity.com/en/news/93189/summit-and-evolva-sign-worldwide-licensing-agreement-in-infectious-diseases-for-imino-sugar-compound-smt-14400.html